Welcome to our dedicated page for Churchill Capital XI news (Ticker: CCXI), a resource for investors and traders seeking the latest updates and insights on Churchill Capital XI stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Churchill Capital XI's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Churchill Capital XI's position in the market.
ChemoCentryx (NASDAQ: CCXI) has announced the identification of CCX559, an orally administered checkpoint inhibitor, with plans to start clinical development in early 2021. Data presented at the AACR meeting revealed that their optimized inhibitors significantly blocked the PD-1/PD-L1 interaction, showing strong anti-tumor effects in animal models. The company aims to develop more convenient and safe therapies to enhance immune responses against tumors, potentially complementing existing antibody therapies.
ChemoCentryx announced the completion of its follow-on offering of 5,200,000 shares at $58.00 per share, raising approximately $325.4 million in net proceeds. The underwriters fully exercised their option to purchase an additional 780,000 shares. This offering allows the company to strengthen its financial position and support the development of its innovative therapies targeting inflammatory and autoimmune diseases and cancer.
ChemoCentryx has priced an underwritten public offering of 5,200,000 shares at $58.00 per share, aiming for gross proceeds of approximately $301.6 million. The underwriters hold a 30-day option to buy an additional 780,000 shares. This offering is set to close on June 15, 2020. The funds raised are intended to further support ChemoCentryx's initiatives in developing treatments for inflammatory and autoimmune diseases and cancer.
ChemoCentryx (Nasdaq: CCXI) has initiated an underwritten public offering of its common stock, with an additional 30-day option for underwriters to purchase up to 15% more shares. The offering is subject to market conditions and will be carried out under a previously filed SEC registration statement effective June 10, 2020. This press release does not constitute an offer to sell or buy securities where it would be unlawful.
The company focuses on developing medications for inflammatory and autoimmune diseases and cancer.
ChemoCentryx (NASDAQ: CCXI) recently presented outcomes from its Phase III ADVOCATE trial during the EULAR and ERA-EDTA virtual meetings. The trial investigated avacopan, a novel treatment for ANCA-associated vasculitis, comparing it to standard therapies over 52 weeks with 331 participants across 20 countries. Avacopan aims to reduce reliance on high-dose corticosteroids while targeting specific inflammatory pathways. The company is also pursuing avacopan for other conditions, having received orphan-drug designations from the FDA and the European Commission.
ChemoCentryx (CCXI) and Vifor Fresenius Medical Care Renal Pharma have released topline results from the LUMINA-1 trial, evaluating CCX140 for primary Focal Segmental Glomerulosclerosis (FSGS). The Phase II study involved 46 patients and found that CCX140 did not significantly lower proteinuria compared to placebo after 12 weeks. Despite the disappointing results for CCX140, ChemoCentryx remains optimistic about its lead drug, avacopan, with plans for an NDA submission for ANCA-associated vasculitis and additional data releases for related renal diseases later this year.
Summary not available.